Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma

Hematology/Oncology Clinics of North America

Volumn 21, Issue 6, 2007, Pages 1093-1113

  Kyle, Robert A ^a   Rajkumar, S Vincent ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENCE JONES PROTEIN; CYTOKINE; IMMUNOGLOBULIN D; IMMUNOGLOBULIN M;

AGAR GEL ELECTROPHORESIS; ANGIOGENESIS; BONE MARROW CELL; CAUSE OF DEATH; CELL COUNT; CONNECTIVE TISSUE DISEASE; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; DISEASE COURSE; ENDOCRINE DISEASE; FOLLOW UP; GAUCHER DISEASE; GENE MUTATION; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; IMMUNE DEFICIENCY; LEUKEMIA; LIFE EXPECTANCY; LYMPHOPROLIFERATIVE DISEASE; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; MYELOID METAPLASIA; NEUROLOGIC DISEASE; PARAPROTEINEMIA; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; PATHOPHYSIOLOGY; PATIENT REFERRAL; PERNICIOUS ANEMIA; PLASMA CELL; POLYCYTHEMIA VERA; PREVALENCE; PRIORITY JOURNAL; PURE RED CELL ANEMIA; PYODERMA GANGRENOSUM; REVIEW; RISK FACTOR; SCLEROMYXEDEMA; VON WILLEBRAND DISEASE; XANTHOGRANULOMA; XANTHOMATOSIS;

ADULT; AGED; AGED, 80 AND OVER; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; MALE; MIDDLE AGED; MINNESOTA; MONOCLONAL GAMMOPATHIES, BENIGN; MULTIPLE MYELOMA; RETROSPECTIVE STUDIES;

EID: 35748932962     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hoc.2007.08.005     Document Type: Review

References (69)

1. Waldenström J. Abnormal proteins in myeloma. Adv Intern Med 5 (1952) 398-440
2. Kyle R.A. Monoclonal gammopathy of undetermined significance. Natural history in 241 cases. Am J Med 64 5 (1978) 814-826
3. Katzmann J.A., Dispenzieri A., Kyle R.A., et al. Elimination of the need for urine studies in the screening algorithm for monoclonal gammopathies by using serum immunofixation and free light chain assays. Mayo Clin Proc 81 12 (2006) 1575-1578
4. Axelsson U., Bachmann R., and Hallen J. Frequency of pathological proteins (M-components) in 6,995 sera from an adult population. Acta Med Scand 179 2 (1966) 235-247
5. Kyle R.A., Finkelstein S., Elveback L.R., et al. Incidence of monoclonal proteins in a Minnesota community with a cluster of multiple myeloma. Blood 40 5 (1972) 719-724
6. Saleun J.P., Vicariot M., Deroff P., et al. Monoclonal gammopathies in the adult population of Finistere, France. J Clin Pathol 35 1 (1982) 63-68
7. Landgren O., Gridley G., Turesson I., et al. Risk of monoclonal gammopathy of undetermined significance (MGUS) and subsequent multiple myeloma among African American and white veterans in the United States. Blood 107 3 (2006) 904-906
8. Kyle R.A., Therneau T.M., Rajkumar S.V., et al. Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med 354 13 (2006) 1362-1369
9. Kyle R.A., Therneau T.M., Rajkumar S.V., et al. Long-term follow-up of 241 patients with monoclonal gammopathy of undetermined significance: the original Mayo Clinic series 25 years later. Mayo Clin Proc 79 7 (2004) 859-866
10. Kyle R.A., Therneau T.M., Rajkumar S.V., et al. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med 346 8 (2002) 564-569
11. Kyle R.A., Gertz M.A., Witzig T.E., et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc 78 1 (2003) 21-33
12. Blade J., Lopez-Guillermo A., Rozman C., et al. Malignant transformation and life expectancy in monoclonal gammopathy of undetermined significance. Br J Haematol 81 3 (1992) 391-394
13. Gregersen H., Ibsen J., Mellemkjoer L., et al. Mortality and causes of death in patients with monoclonal gammopathy of undetermined significance. Br J Haematol 112 2 (2001) 353-357
14. Gregersen H., Mellemkjaer L., Salling Ibsen J., et al. Cancer risk in patients with monoclonal gammopathy of undetermined significance. Am J Hematol 63 1 (2000) 1-6
15. Ogmundsdottir H.M., and Haraldsdottir V. Monoclonal gammopathy in Iceland: a population-based registry and follow-up. Br J Haematol 118 1 (2002) 166-173
16. Kyle R.A., and Rajkumar S.V. Monoclonal gammopathy of undetermined significance. Br J Haematol 134 6 (2006) 573-589
17. Avet-Loiseau H., Li J.Y., Facon T., et al. High incidence of translocations t(11;14)(q13;q32) and t(4;14)(p16;q32) in patients with plasma cell malignancies. Cancer Res 58 24 (1998) 5640-5645
18. Avet-Loiseau H., Facon T., Daviet A., et al. 14q32 translocations and monosomy 13 observed in monoclonal gammopathy of undetermined significance delineate a multistep process for the oncogenesis of multiple myeloma. Intergroupe Francophone du Myelome. Cancer Res 59 18 (1999) 4546-4550
19. Chng W.J., Van Wier S.A., Ahmann G.J., et al. A validated FISH trisomy index demonstrates the hyperdiploid and nonhyperdiploid dichotomy in MGUS. Blood 106 6 (2005) 2156-2161
20. Avet-Loiseau H., Li J.Y., Morineau N., et al. Monosomy 13 is associated with the transition of monoclonal gammopathy of undetermined significance to multiple myeloma. Intergroupe Francophone du Myelome. Blood 94 8 (1999) 2583-2589
21. Rasmussen T., Kuehl M., Lodahl M., et al. Possible roles for activating RAS mutations in the MGUS to MM transition and in the intramedullary to extramedullary transition in some plasma cell tumors. Blood 105 1 (2005) 317-323
22. Melton III L.J., Rajkumar S.V., Khosla S., et al. Fracture risk in monoclonal gammopathy of undetermined significance. J Bone Miner Res 19 1 (2004) 25-30
23. Roodman III G.D. Biology of myeloma bone disease. In: Broudy V.C., Abkowitz J.L., and Vose J.M. (Eds). Hematology 2002: American Society of Hematology Education Program Book (2002), Blood, Washington, DC 227-232
24. Croucher P.I., Shipman C.M., Lippitt J., et al. Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma. Blood 98 13 (2001) 3534-3540
25. Vacca A., Ribatti D., Roncali L., et al. Bone marrow angiogenesis and progression in multiple myeloma. Br J Haematol 87 3 (1994) 503-508
26. Rajkumar S.V., Mesa R.A., Fonseca R., et al. Bone marrow angiogenesis in 400 patients with monoclonal gammopathy of undetermined significance, multiple myeloma, and primary amyloidosis. Clin Cancer Res 8 7 (2002) 2210-2216
27. Kumar S., Witzig T.E., Timm M., et al. Bone marrow angiogenic ability and expression of angiogenic cytokines in myeloma: evidence favoring loss of marrow angiogenesis inhibitory activity with disease progression. Blood 104 4 (2004) 1159-1165
28. Malik A.A., Ganti A.K., Potti A., et al. Role of Helicobacter pylori infection in the incidence and clinical course of monoclonal gammopathy of undetermined significance. Am J Gastroenterol 97 6 (2002) 1371-1374
29. Rajkumar S.V., Kyle R.A., Plevak M.F., et al. Helicobacter pylori infection and monoclonal gammopathy of undetermined significance. Br J Haematol 119 3 (2002) 706-708
30. Kyle R.A. "Benign" monoclonal gammopathy-after 20 to 35 years of follow-up. Mayo Clin Proc 68 1 (1993) 26-36
31. Cesana C., Klersy C., Barbarano L., et al. Prognostic factors for malignant transformation in monoclonal gammopathy of undetermined significance and smoldering multiple myeloma. J Clin Oncol 20 6 (2002) 1625-1634
32. Baldini L., Guffanti A., Cesana B.M., et al. Role of different hematologic variables in defining the risk of malignant transformation in monoclonal gammopathy. Blood 87 3 (1996) 912-918
33. Rajkumar S.V., Kyle R.A., Therneau T.M., et al. Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance. Blood 106 3 (2005) 812-817
34. Kumar S., Rajkumar S.V., Kyle R.A., et al. Prognostic value of circulating plasma cells in monoclonal gammopathy of undetermined significance. J Clin Oncol 23 24 (2005) 5668-5674
35. Rajkumar S.V., Dispenzieri A., and Kyle R.A. Monoclonal gammopathy of undetermined significance, Waldenström macroglobulinemia, AL amyloidosis, and related plasma cell disorders: diagnosis and treatment. Mayo Clin Proc 81 5 (2006) 693-703
36. Kyle R.A., and Garton J.P. The spectrum of IgM monoclonal gammopathy in 430 cases. Mayo Clin Proc 62 8 (1987) 719-731
37. Gobbi P.G., Baldini L., Broglia C., et al. Prognostic validation of the international classification of immunoglobulin M gammopathies: a survival advantage for patients with immunoglobulin M monoclonal gammopathy of undetermined significance?. Clin Cancer Res 11 5 (2005) 1786-1790
38. Kyle R.A., Therneau T.M., Rajkumar S.V., et al. Long-term follow-up of IgM monoclonal gammopathy of undetermined significance. Blood 102 10 (2003) 3759-3764
39. Morra E., Cesana C., Klersy C., et al. Prognostic factors for transformation in asymptomatic immunoglobulin M monoclonal gammopathies. Clin Lymphoma 5 4 (2005) 265-269
40. Cesana C., Barbarano L., Miqueleiz S., et al. Clinical characteristics and outcome of immunoglobulin M-related disorders. Clin Lymphoma 5 4 (2005) 261-264
41. Baldini L., Goldaniga M., Guffanti A., et al. Immunoglobulin M monoclonal gammopathies of undetermined significance and indolent Waldenström's macroglobulinemia recognize the same determinants of evolution into symptomatic lymphoid disorders: proposal for a common prognostic scoring system. J Clin Oncol 23 21 (2005) 4662-4668
42. Kyle R.A., Robinson R.A., and Katzmann J.A. The clinical aspects of biclonal gammopathies. Review of 57 cases. Am J Med 71 6 (1981) 999-1008
43. Grosbois B., Jego P., de Rosa H., et al. [Triclonal gammopathy and malignant immunoproliferative syndrome]. [review]. Revue de Medecine Interne 18 6 (1997) 470-473 [in French]
44. Tirelli A., Guastafierro S., Cava B., et al. Triclonal gammopathy in an extranodal non-Hodgkin lymphoma patient. Am J Hematol 73 4 (2003) 273-275
45. Kyle R.A., and Greipp P.R. "Idiopathic" Bence Jones proteinuria: long-term follow-up in seven patients. N Engl J Med 306 10 (1982) 564-567
46. Alexanian R. Monoclonal gammopathy in lymphoma. Arch Intern Med 135 1 (1975) 62-66
47. Lin P., Hao S., Handy B.C., et al. Lymphoid neoplasms associated with IgM paraprotein: a study of 382 patients. Am J Clin Pathol 123 2 (2005) 200-205
48. Asatiani E., Cohen P., Ozdemirli M., et al. Monoclonal gammopathy in extranodal marginal zone lymphoma (ENMZL) correlates with advanced disease and bone marrow involvement. Am J Hematol 77 2 (2004) 144-146
49. Noel P., and Kyle R.A. Monoclonal proteins in chronic lymphocytic leukemia. Am J Clin Pathol 87 3 (1987) 385-388
50. Lamboley V., Zabraniecki L., Sie P., et al. Myeloma and monoclonal gammopathy of uncertain significance associated with acquired von Willebrand's syndrome. Seven new cases with a literature review. Joint Bone Spine 69 1 (2002) 62-67
51. Sallah S., Husain A., Wan J., et al. The risk of venous thromboembolic disease in patients with monoclonal gammopathy of undetermined significance. Ann Oncol 15 10 (2004) 1490-1494
52. Kelly Jr. J.J., Kyle R.A., O'Brien P.C., et al. Prevalence of monoclonal protein in peripheral neuropathy. Neurology 31 11 (1981) 1480-1483
53. Quarles R.H., and Weiss M.D. Autoantibodies associated with peripheral neuropathy. [review]. Muscle Nerve 22 7 (1999) 800-822
54. Gosselin S., Kyle R.A., and Dyck P.J. Neuropathy associated with monoclonal gammopathies of undetermined significance. Ann Neurol 30 1 (1991) 54-61
55. Nobile-Orazio E. Treatment of dys-immune neuropathies. J Neurol 252 4 (2005) 385-395
56. Dispenzieri A., Kyle R.A., Lacy M.Q., et al. POEMS syndrome: definitions and long-term outcome. Blood 101 7 (2003) 2496-2506
57. Daoud M.S., Lust J.A., Kyle R.A., et al. Monoclonal gammopathies and associated skin disorders. [review]. J Am Acad Dermatol 40 4 (1999) 507-535
58. Mundis R.J., and Kyle R.A. Primary hyperparathyroidism and monoclonal gammopathy of undetermined significance. Am J Clin Pathol 77 5 (1982) 619-621
59. Arnulf B., Bengoufa D., Sarfati E., et al. Prevalence of monoclonal gammopathy in patients with primary hyperparathyroidism: a prospective study. Arch Intern Med 162 4 (2002) 464-467
60. Badley A.D., Portela D.F., Patel R., et al. Development of monoclonal gammopathy precedes the development of Epstein-Barr virus-induced posttransplant lymphoproliferative disorder. Liver Transpl Surg 2 5 (1996) 375-382
61. Zent C.S., Wilson C.S., Tricot G., et al. Oligoclonal protein bands and Ig isotype switching in multiple myeloma treated with high-dose therapy and hematopoietic cell transplantation. Blood 91 9 (1998) 3518-3523
62. Rostaing L., Modesto A., Abbal M., et al. Long-term follow-up of monoclonal gammopathy of undetermined significance in transplant patients. Am J Nephrol 14 3 (1994) 187-191
63. Pascual M., Widmann J.J., and Schifferli J.A. Recurrent febrile panniculitis and hepatitis in two patients with acquired complement deficiency and paraproteinemia. Am J Med 83 5 (1987) 959-962
64. Droder R.M., Kyle R.A., and Greipp P.R. Control of systemic capillary leak syndrome with aminophylline and terbutaline. Am J Med 92 5 (1992) 523-526
65. Dingli D., Larson D.R., Plevak M.F., et al. Focal and segmental glomerulosclerosis and plasma cell proliferative disorders. Am J Kidney Dis 46 2 (2005) 278-282
66. Karlson E.W., Tanasijevic M., Hankinson S.E., et al. Monoclonal gammopathy of undetermined significance and exposure to breast implants. Arch Intern Med 161 6 (2001) 864-867
67. Merlini G., Farhangi M., and Osserman E.F. Monoclonal immunoglobulins with antibody activity in myeloma, macroglobulinemia and related plasma cell dyscrasias. [review]. Semin Oncol 13 3 (1986) 350-365
68. Dimopoulos M.A., Moulopoulos L.A., Maniatis A., et al. Solitary plasmacytoma of bone and asymptomatic multiple myeloma. Blood 96 6 (2000) 2037-2044
69. Kyle R.A., Linos A., Beard C.M., et al. Incidence and natural history of primary systemic amyloidosis in Olmsted County, Minnesota, 1950 through 1989. Blood 79 7 (1992) 1817-1822